Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

• Fernando Magro,
• Jakob Begun,
• Edouard Louis,
• Simon PL Travis,
• Alexander R Moschen,
• Neeraj Narula,
• Grazyna Rydzewska,
• Jae Hee Cheon,
• Kristine Paridaens,
• Sameer Al Awadhi,
• Axel U Dignass,
• Juan Ricardo Márquez,
• Matthew J Freddi

Affiliations

Fernando Magro

Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of Porto, Porto, Portugal

Jakob Begun

Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia

Edouard Louis

Hepato-Gastroenterology and Digestive Oncology Department, University and Centre Hospitalier Univestitaire (CHU) Liège, Liège, Belgium

Simon PL Travis

NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Alexander R Moschen

University Clinic for Internal Medicine, Johannes Kepler University, Linz, Austria

Neeraj Narula

Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada

Grazyna Rydzewska

Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, The Central Clinical Hospital of the Ministry of the Interior Affairs and Administration, Warsaw, Poland

Jae Hee Cheon

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of)

Kristine Paridaens

Ferring International Center SA, Saint-Prex, Switzerland

Sameer Al Awadhi

Gastroenterology Department, Rashid Hospital, Dubai, UAE

Axel U Dignass

Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany

Juan Ricardo Márquez

Colorectal Surgery Department, Instituto de Coloproctologia ICO Clinica Las Americas, Medellin, Colombia

Matthew J Freddi

Violicom Medical Limited, Aldermaston, UK